Drug Combination Details
| General Information of the Combination (ID: C69357) | |||||
|---|---|---|---|---|---|
| Name | Osthole NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
|
Rhabdomyosarcoma
[ICD-11: 2B55]
|
Investigative | [2] | |||
|
Cervical cancer
[ICD-11: 2C77]
|
Investigative | [3] | |||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [4] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | GABPA | Molecule Info | |||
| Down-regulation | Expression | MKI67 | Molecule Info | |||
| Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SiHa | CVCL_0032 | Cervical squamous cell carcinoma | Homo sapiens | ||
| Ca Ski | CVCL_1100 | Cervical squamous cell carcinoma | Homo sapiens | |||
| In-vivo Model | SiHa/CDDP cells (1*106) suspended in cold PBS were subcutaneously injected to the right armpit of mice (female BALB/c nude mice). | |||||
| Experimental
Result(s) |
Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The combination of osthole and cisplatin resulted in greater efficacy in growth inhibition and apoptosis induction. | |||||
| Experiment 3 Reporting the Effect of This Combination | [2] | |||||
| In-vitro Model | TE 671 | CVCL_1756 | Rhabdomyosarcoma | Homo sapiens | ||
| Experimental
Result(s) |
Combination of Osthole and Cisplatin against rhabdomyosarcoma TE671 cells yielded additive pharmacologic interaction by means of isobolographic analysis. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PTEN | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | CD133 positive Huh7 cells were inoculated subcutaneously into the BALB/c nude mice. | |||||
| Experimental
Result(s) |
Combination treatment with osthole can resensitize CD133+ HCC cells to cisplatin treatment via the PTEN/AKT pathway. | |||||
